@article{3020002,
    title = "Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents",
    author = "Briasoulis, A. and Chasouraki, A. and Sianis, A. and Panagiotou, N. and Kourek, C. and Ntalianis, A. and Paraskevaidis, I.",
    journal = "Journal of Cardiovascular Development and Disease",
    year = "2022",
    volume = "9",
    number = "3",
    publisher = "MDPI",
    doi = "10.3390/jcdd9030066",
    keywords = "antineoplastic agent;  BCR ABL protein;  cell therapy agent;  epidermal growth factor receptor 2;  epidermal growth factor receptor kinase inhibitor;  immune checkpoint inhibitor;  proteasome inhibitor;  protein tyrosine kinase inhibitor;  vasculotropin inhibitor, cancer chemotherapy;  cancer immunotherapy;  cancer prognosis;  cardiomyopathy;  cardiotoxicity;  chimeric antigen receptor T-cell immunotherapy;  heart protection;  human;  malignant neoplasm;  molecularly targeted therapy;  myocarditis;  nonhuman;  primary prevention;  Review;  screening;  secondary prevention",
    abstract = "Throughout the last decades, newly developed chemotherapeutic agents and immunother-apies that target signaling pathways have provided patients with better prognoses, improved their quality of life and increased survival rates, thus converting cancer to a stable chronic disease. However, non-anthracycline cancer chemotherapy agents and immunotherapies including human epidermal growth factor receptor 2 (HER2) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), proteasome inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells (CAR-T cells) may cause cardiovascular toxicity events and complications that usually interrupt the continuation of an appropriate treatment regimen, which induces life-threatening risks or leads to long-term morbidity. Heart failure, cardiac arrythmias and cardiomy-opathies are the most common cardiovascular events related to cardiotoxicity due to chemotherapy. Each patient should be carefully assessed and monitored before, during and after the administra-tion of chemotherapy, to address any predisposing risk factors and the new onset of cardiotoxicity manifestations early and treat them appropriately. The development of novel anticancer agents that cause minimal cardiovascular toxicity events or novel agents that ameliorate the adverse effects of the existing anticancer agents could drastically change the field of cardio-oncology. The aim of this narrative review is to demonstrate new knowledge regarding the screening and diagnosis of non-anthracycline-induced cardiotoxicity and to propose protective measures that could be performed in order to achieve the delivery of optimal care. © 2022 by the authors. Licensee MDPI, Basel, Switzerland."
}